Global Aflibercept Drug 麻豆原创 Research Report 2023

Publication ID:

PB510230662

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer.
The global Aflibercept Drug market is projected to reach US$ 7305.9 million in 2029, increasing from US$ 5617 million in 2022, with the CAGR of 3.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Aflibercept Drug market research.
The Eylea market is primarily driven by the increasing prevalence of retinal diseases and the demand for effective treatments. Eylea (aflibercept) is a medication used to treat various eye conditions, including wet age-related macular degeneration (AMD) and diabetic macular edema. The growing aging population and the rise in chronic diseases like diabetes contribute to market growth. Moreover, advancements in ocular therapeutics and the demonstrated efficacy of Eylea in improving visual outcomes further propel adoption. However, challenges include managing the high cost of treatment and ensuring equitable access to care. Navigating the competitive landscape, optimizing treatment protocols, and addressing potential side effects are ongoing concerns. The market's success relies on continuous research to expand the indications for Eylea, collaborations between pharmaceutical manufacturers and ophthalmologists, and comprehensive patient education on the benefits and potential risks of treatment while addressing the evolving challenges associated with retinal disease management and treatment affordability.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Aflibercept Drug market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Regeneron
Bayer
Sanofi
Segment by Type
Prefilled Syring Package
Vial Package
Segment by Application
Eye Disease
Cancer
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Aflibercept Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers鈥� Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers鈥� Outline
Chapter 7: Industry Chain, 麻豆原创 Channel and Customer Analysis
Chapter 8: 麻豆原创 Opportunities and Challenges
Chapter 9: 麻豆原创 Conclusions
Chapter 10: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Aflibercept Drug 麻豆原创 Overview
1.1 Product Overview and Scope of Aflibercept Drug
1.2 Aflibercept Drug Segment by Type
1.2.1 Global Aflibercept Drug 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Prefilled Syring Package
1.2.3 Vial Package
1.3 Aflibercept Drug Segment by Application
1.3.1 Global Aflibercept Drug 麻豆原创 Value by Application: (2023-2029)
1.3.2 Eye Disease
1.3.3 Cancer
1.4 Global Aflibercept Drug 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Aflibercept Drug Revenue 2018-2029
1.4.2 Global Aflibercept Drug Sales 2018-2029
1.4.3 Global Aflibercept Drug 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Aflibercept Drug 麻豆原创 Competition by Manufacturers
2.1 Global Aflibercept Drug Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Aflibercept Drug Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Aflibercept Drug Average Price by Manufacturers (2018-2023)
2.4 Global Aflibercept Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Aflibercept Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Aflibercept Drug, Product Type & Application
2.7 Aflibercept Drug 麻豆原创 Competitive Situation and Trends
2.7.1 Aflibercept Drug 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Aflibercept Drug Players 麻豆原创 Share by Revenue
2.7.3 Global Aflibercept Drug 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Aflibercept Drug Retrospective 麻豆原创 Scenario by Region
3.1 Global Aflibercept Drug 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Aflibercept Drug Global Aflibercept Drug Sales by Region: 2018-2029
3.2.1 Global Aflibercept Drug Sales by Region: 2018-2023
3.2.2 Global Aflibercept Drug Sales by Region: 2024-2029
3.3 Global Aflibercept Drug Global Aflibercept Drug Revenue by Region: 2018-2029
3.3.1 Global Aflibercept Drug Revenue by Region: 2018-2023
3.3.2 Global Aflibercept Drug Revenue by Region: 2024-2029
3.4 North America Aflibercept Drug 麻豆原创 Facts & Figures by Country
3.4.1 North America Aflibercept Drug 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Aflibercept Drug Sales by Country (2018-2029)
3.4.3 North America Aflibercept Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Aflibercept Drug 麻豆原创 Facts & Figures by Country
3.5.1 Europe Aflibercept Drug 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Aflibercept Drug Sales by Country (2018-2029)
3.5.3 Europe Aflibercept Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Aflibercept Drug 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Aflibercept Drug 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Aflibercept Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Aflibercept Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Aflibercept Drug 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Aflibercept Drug 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Aflibercept Drug Sales by Country (2018-2029)
3.7.3 Latin America Aflibercept Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Aflibercept Drug 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Aflibercept Drug 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Aflibercept Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Aflibercept Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Aflibercept Drug Sales by Type (2018-2029)
4.1.1 Global Aflibercept Drug Sales by Type (2018-2023)
4.1.2 Global Aflibercept Drug Sales by Type (2024-2029)
4.1.3 Global Aflibercept Drug Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Aflibercept Drug Revenue by Type (2018-2029)
4.2.1 Global Aflibercept Drug Revenue by Type (2018-2023)
4.2.2 Global Aflibercept Drug Revenue by Type (2024-2029)
4.2.3 Global Aflibercept Drug Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Aflibercept Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Aflibercept Drug Sales by Application (2018-2029)
5.1.1 Global Aflibercept Drug Sales by Application (2018-2023)
5.1.2 Global Aflibercept Drug Sales by Application (2024-2029)
5.1.3 Global Aflibercept Drug Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Aflibercept Drug Revenue by Application (2018-2029)
5.2.1 Global Aflibercept Drug Revenue by Application (2018-2023)
5.2.2 Global Aflibercept Drug Revenue by Application (2024-2029)
5.2.3 Global Aflibercept Drug Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Aflibercept Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Regeneron
6.1.1 Regeneron Corporation Information
6.1.2 Regeneron Description and Business Overview
6.1.3 Regeneron Aflibercept Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Regeneron Aflibercept Drug Product Portfolio
6.1.5 Regeneron Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Aflibercept Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bayer Aflibercept Drug Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Aflibercept Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Aflibercept Drug Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Aflibercept Drug Industry Chain Analysis
7.2 Aflibercept Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Aflibercept Drug Production Mode & Process
7.4 Aflibercept Drug Sales and 麻豆原创ing
7.4.1 Aflibercept Drug Sales Channels
7.4.2 Aflibercept Drug Distributors
7.5 Aflibercept Drug Customers
8 Aflibercept Drug 麻豆原创 Dynamics
8.1 Aflibercept Drug Industry Trends
8.2 Aflibercept Drug 麻豆原创 Drivers
8.3 Aflibercept Drug 麻豆原创 Challenges
8.4 Aflibercept Drug 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Regeneron
Bayer
Sanofi

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.